Full Text View
Tabular View
No Study Results Posted
Related Studies
DIabetic Retinopathy Candesartan Trials. (DIRECT)
This study has been completed.
Study NCT00252720   Information provided by AstraZeneca
First Received: November 10, 2005   Last Updated: March 9, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Type 1 Diabetes
Additional conditions recognized in this trial
Diabetes Mellitus, Type 1
Diabetic Retinopathy
Retinal Diseases
More general conditions related to this trial
Autoimmune Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Diabetic Angiopathies
Endocrine System Diseases
Eye Diseases
Glucose Metabolism Disorders
Immune System Diseases
Metabolic Diseases
Vascular Diseases
Interventions listed in this trial
Candesartan Cilexetil
Additional drug interventions recognized in this trial
Candesartan
More general drug interventions related to this trial
Angiotensin II Type 1 Receptor Blockers
Antihypertensive Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
AstraZeneca
Takeda Global Research &Development Center, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services